Related Experiment Video
Updated: Aug 15, 2026

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
Published on: November 7, 2025
[Vaccine therapy of prostate cancer]
C Doehn1, T Böhmer, M Sommerauer
1Klinik und Poliklinik für Urologie, Universitätsklinikum Schleswig-Holstein (UKSH), Campus Lübeck. doehn@medinf.mu-luebeck.de
Abstract:
Vaccine therapy of prostate cancer has been increasingly studied in trials over the past few years. The different vaccine techniques are quite variable and are predominantly used in patients with advanced hormone-refractory prostate cancer. In this review, vaccine techniques using tumor cells, dendritic cells or poxvirus are analyzed. For theses approaches phase-III trials are being planned, have been initiated or are already completed. Many trials demonstrate the efficacy with regard to endpoints such as stimulation of the immune system and/or biochemical response and/or clinical response. Recently, one vaccine approach using autologous dendritic cells demonstrated a statistically significant prolongation of overall survival compared to placebo in patients with hormone-refractory prostate cancer. Side effects of vaccination are generally mild. At present, there are trials are being planned or are already ongoing that combine vaccine with other treatment strategies or enroll patients with earlier disease stages.
Insights
Prostate cancer vaccine therapy shows promise, with some approaches demonstrating significant survival benefits in advanced stages. Further trials are exploring combinations and earlier disease interventions for improved outcomes.
Area of Science:
- Oncology
- Immunology
- Vaccinology
Background:
- Prostate cancer vaccine therapy is an evolving field.
- Current research focuses on advanced, hormone-refractory prostate cancer.
- Various vaccine types are under investigation.
Purpose of the Study:
- To review current vaccine techniques for prostate cancer.
- To analyze the efficacy and safety of different vaccine approaches.
- To discuss ongoing and planned clinical trials.
Main Methods:
- Review of vaccine techniques including tumor cells, dendritic cells, and poxvirus.
- Analysis of Phase-III trial data (planned, initiated, completed).
- Evaluation of immune stimulation, biochemical, and clinical responses.
Main Results:
- Multiple vaccine trials show efficacy in immune, biochemical, and clinical responses.
- Autologous dendritic cell vaccine significantly prolonged overall survival in hormone-refractory prostate cancer.
- Vaccination side effects are generally mild.
Conclusions:
- Prostate cancer vaccine therapy demonstrates potential, particularly in advanced disease.
- Ongoing trials are investigating combination therapies and earlier disease stages.
- Vaccine therapy represents a promising avenue for prostate cancer treatment.
More Related Videos
Related Concept Videos
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Tumor Immunotherapy
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...

